Thomas Smith
Stock Analyst at Leerink Partners
(2.27)
# 2,727
Out of 4,996 analysts
68
Total ratings
29.03%
Success rate
14.06%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Thomas Smith
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RAPT RAPT Therapeutics | Upgrades: Outperform | $16 → $37 | $26.38 | +40.26% | 3 | Sep 26, 2025 | |
| EQ Equillium | Downgrades: Market Perform | $3 → $1 | $1.50 | -33.33% | 4 | Mar 28, 2025 | |
| QTTB Q32 Bio | Downgrades: Market Perform | $68 → $9 | $1.89 | +376.19% | 2 | Dec 11, 2024 | |
| ACRS Aclaris Therapeutics | Upgrades: Outperform | $2 → $7 | $1.99 | +251.76% | 7 | Nov 19, 2024 | |
| ALMS Alumis | Initiates: Outperform | $29 | $4.05 | +616.05% | 1 | Jul 23, 2024 | |
| RNAC Cartesian Therapeutics | Initiates: Outperform | $39 | $9.26 | +321.17% | 1 | Apr 23, 2024 | |
| SGMT Sagimet Biosciences | Initiates: Outperform | $26 | $7.34 | +254.22% | 1 | Mar 25, 2024 | |
| ABVX ABIVAX Société Anonyme | Initiates: Outperform | $20 | $82.84 | -75.86% | 1 | Nov 14, 2023 | |
| ARGX argenx SE | Maintains: Outperform | $430 → $435 | $712.03 | -38.91% | 3 | Mar 3, 2023 | |
| IRON Disc Medicine | Initiates: Outperform | $36 | $65.55 | -45.08% | 1 | Feb 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $9 → $7 | $1.58 | +343.04% | 4 | Feb 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $14 → $21 | $16.23 | +29.39% | 6 | Feb 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $45 | $20.18 | +122.99% | 2 | Jan 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $6 | $8.77 | -31.58% | 1 | Nov 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $5 → $6 | $5.53 | +8.50% | 2 | Nov 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $9 → $5 | $0.94 | +432.42% | 3 | Oct 21, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $17 | $61.99 | -72.58% | 1 | Aug 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $68 → $64 | $26.14 | +144.84% | 2 | Aug 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $66 → $70 | $16.76 | +317.66% | 5 | Aug 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $50 → $29 | $14.70 | +97.28% | 5 | Jul 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $33 → $26 | $2.69 | +866.54% | 3 | Jun 1, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $18 → $12 | $25.57 | -53.07% | 2 | Apr 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $10 | $3.45 | +189.86% | 4 | Apr 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $675 → $400 | $4.41 | +8,970.29% | 2 | Mar 16, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $42 → $80 | $16.05 | +398.44% | 2 | Dec 8, 2020 |
RAPT Therapeutics
Sep 26, 2025
Upgrades: Outperform
Price Target: $16 → $37
Current: $26.38
Upside: +40.26%
Equillium
Mar 28, 2025
Downgrades: Market Perform
Price Target: $3 → $1
Current: $1.50
Upside: -33.33%
Q32 Bio
Dec 11, 2024
Downgrades: Market Perform
Price Target: $68 → $9
Current: $1.89
Upside: +376.19%
Aclaris Therapeutics
Nov 19, 2024
Upgrades: Outperform
Price Target: $2 → $7
Current: $1.99
Upside: +251.76%
Alumis
Jul 23, 2024
Initiates: Outperform
Price Target: $29
Current: $4.05
Upside: +616.05%
Cartesian Therapeutics
Apr 23, 2024
Initiates: Outperform
Price Target: $39
Current: $9.26
Upside: +321.17%
Sagimet Biosciences
Mar 25, 2024
Initiates: Outperform
Price Target: $26
Current: $7.34
Upside: +254.22%
ABIVAX Société Anonyme
Nov 14, 2023
Initiates: Outperform
Price Target: $20
Current: $82.84
Upside: -75.86%
argenx SE
Mar 3, 2023
Maintains: Outperform
Price Target: $430 → $435
Current: $712.03
Upside: -38.91%
Disc Medicine
Feb 28, 2023
Initiates: Outperform
Price Target: $36
Current: $65.55
Upside: -45.08%
Feb 8, 2023
Maintains: Outperform
Price Target: $9 → $7
Current: $1.58
Upside: +343.04%
Feb 6, 2023
Maintains: Outperform
Price Target: $14 → $21
Current: $16.23
Upside: +29.39%
Jan 9, 2023
Maintains: Outperform
Price Target: $40 → $45
Current: $20.18
Upside: +122.99%
Nov 22, 2022
Initiates: Outperform
Price Target: $6
Current: $8.77
Upside: -31.58%
Nov 9, 2022
Maintains: Outperform
Price Target: $5 → $6
Current: $5.53
Upside: +8.50%
Oct 21, 2022
Downgrades: Market Perform
Price Target: $9 → $5
Current: $0.94
Upside: +432.42%
Aug 25, 2022
Initiates: Outperform
Price Target: $17
Current: $61.99
Upside: -72.58%
Aug 9, 2022
Maintains: Outperform
Price Target: $68 → $64
Current: $26.14
Upside: +144.84%
Aug 9, 2022
Maintains: Outperform
Price Target: $66 → $70
Current: $16.76
Upside: +317.66%
Jul 11, 2022
Maintains: Outperform
Price Target: $50 → $29
Current: $14.70
Upside: +97.28%
Jun 1, 2022
Maintains: Outperform
Price Target: $33 → $26
Current: $2.69
Upside: +866.54%
Apr 28, 2022
Maintains: Outperform
Price Target: $18 → $12
Current: $25.57
Upside: -53.07%
Apr 11, 2022
Maintains: Outperform
Price Target: $15 → $10
Current: $3.45
Upside: +189.86%
Mar 16, 2021
Maintains: Outperform
Price Target: $675 → $400
Current: $4.41
Upside: +8,970.29%
Dec 8, 2020
Maintains: Outperform
Price Target: $42 → $80
Current: $16.05
Upside: +398.44%